Other Team Members

Through developing core integrated care standards and, by ensuring the appropriate financing, tools, and training, these recommendations support and incentivize providers to deliver integrated care, which ultimately benefits Americans struggling with mental illness and substance use.

This research report from NIDA discusses effective prevention and treatment strategies for opioid misuse and use disorder, and overcoming the misunderstandings and other barriers that prevent wider adoption of these treatments.

This NIDA policy brief shares evidence-based research on treating opioud use dissorder on pregnancy, including the assessment of methadone and buprenorphine as treatment.

This brief describes the Screening, Brief Intervention, and Referral to Treatment (SBIRT) model for pregnant and postpartum women with substance use disorders and how to implement and integrate SBIRT into care delivery.

This report aims to address the treatment opportunities for pregnant and postpartum (or parenting) women (PPW) with substance use disorder (SUD) by describing opportunities to integrate obstetricians and gynecologists (OB/GYN) and SUD care as well as barriers to integrated care delivery.

SAMHSA offers evidence-based resources to help providers screen, diagnose, and deliver integrated care to patients with co-occurring disorders.

The following checklist intends to support health care teams in providing evidence-based recommendations for treating pregnant and postpartum patients with OUD. The checklist is divided into five sections, sequenced by timing of presentation to care.

This screening device is often used as a way to begin discussion about drug and alcohol use. Any woman who answers yes to one or more questions should be referred for further assessment.

This revised version of the CRAFFT screening tool incorporates changes that enhance the sensitivity of this well-validated and widely-utilized adolescent substance use screening tool to accurately identify adolescents at risk for a substance use disorder. It also presents new recommended clinician talking points, informed by the latest science and clinician feedback.

The Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) Tool consists of a combined screening component (TAPS-1) followed by a brief assessment (TAPS-2) for those who screen positive.